title: Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
abstract: We measured serum cytokeratin fragment 21-1 (CYFRA 21-1) levels by a solid-phase immunoradiometric assay in 102 healthy Japanese women, and set the reference value at 1.9 ng/ml (mean +2 SD of the serum levels based on a linear distribution). Pretreatment serum CYFRA 21-1 levels were also analyzed in 235 women with benign (n = 94) or malignant (n = 141) gynecologic disease, and were compared with the serum levels of CA 125 and SCC. The respective positivity rates for CYFRA 21-1 and CA 125 were 64.0 and 77.2% in ovarian malignancy, while they were 4.2 and 30.8% in benign ovarian masses. CYFRA 21-1 had an accuracy of 61.3% in diagnosing ovarian malignancy, which was higher than that of CA 125 (53.4%). The positive predictive value of CYFRA 21-1 for ovarian malignancy reached 94.1%, which was significantly (p < 0.005) higher than that of CA 125 (68.8%). These findings indicate the potential usefulness of CYFRA 21-1 as a tumor marker for ovarian malignancy. In addition, the positivity rates fo CYFRA 21-1 in cervical cancer (51.2%) and endometrial cancer (52.2%) were also similar to the respective rates for SCC and CA 125, which suggests that CYFRA 21-1 seems to be a general tumor marker for gynecologic malignancy.
authors.affiliation: Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Tochigi, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Inaba
authors.forename: Y
authors.initials: Y
authors.lastname: Negishi
authors.forename: I
authors.initials: I
authors.lastname: Fukasawa
authors.forename: Y
authors.initials: Y
authors.lastname: Okajima
authors.forename: Y
authors.initials: Y
authors.lastname: Ota
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Matsui
authors.forename: H
authors.initials: H
authors.lastname: Iwasaki
authors.forename: H
authors.initials: H
authors.lastname: Sudo
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D003560:Cysts / Q000097:blood / Q000175:diagnosis; D016889:Endometrial Neoplasms / Q000097:blood / Q000175:diagnosis; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000175:diagnosis; D006801:Humans; D015592:Immunoradiometric Assay / Q000379:methods; D007633:Keratins / Q000097:blood*; D008875:Middle Aged; D010049:Ovarian Diseases / Q000097:blood / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis; D012016:Reference Values; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000175:diagnosis; D014591:Uterine Diseases / Q000097:blood / Q000175:diagnosis; D014594:Uterine Neoplasms / Q000097:blood / Q000175:diagnosis
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D007633:Keratins